Analyst consensus rating
Sagimet Biosciences Analyst Rating: Strong Buy
Direct answer
Sagimet Biosciences's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $27.27.
Forecast evidence checked November 18, 2026.
Get free Sagimet Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.85
- Average price target
- $27.27
- High price target
- $50.00
- Low price target
- $7.00
- Low target gap
- -28.9%
- Target upside
- +176.9%
- High target gap
- +407.6%
- Target range width
- 436.5%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- November 18, 2026
- Valid through
- November 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Sagimet Biosciences?
Sagimet Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $27.27.
How far are Sagimet Biosciences's low and high targets from the recorded price?
The low target implies -28.9%, while the high target implies +407.6%.
How many analysts are included in Sagimet Biosciences's consensus?
The verified consensus includes 11 analysts.
How is Sagimet Biosciences's target upside or downside calculated?
The average target of $27.27 is divided by the recorded price of $9.85, then one is subtracted to produce +176.9%. This does not guarantee a future return.
When was Sagimet Biosciences's analyst forecast verified?
The data was verified on 2026-11-18. The dataset is valid through 2026-11-25.